EQRX News and Press, EQRx Inc. From 07/28/22

CAMBRIDGE, Mass., July 28, 2022 (GLOBE NEWSWIRE) -- EQRx, Inc. (Nasdaq: EQRX), a new type of pharmaceutical company committed to developing and delivering innovative medicines to patients at radically lower prices, today announced it will host a conference call and webcast on Thursday, ...

Buying Penny Stocks in June? What You Need to Know If you’re looking for the best penny stocks to buy in June, there are a few things you need to know. First, penny stocks are volatile and can be risky. Second, there are a lot of penny stocks to choose from, so it’s import...

The U.K.'s Medicines and Healthcare products Regulatory Agency (MHRA) accepted to review EQRx (NASDAQ:EQRX) application seeking approval of aumolertinib to treat certain patients with non-small cell lung cancer (NSCLC). The company had filed a marketing authorization application (MAA) fo...

Marketing authorization application is EQRx’s first submission to a regulatory agency Application is based on data from pivotal Phase 3 AENEAS trial in the first-line treatment of EGFR-mutated non-small cell lung cancer CAMBRIDGE, Mass., June 14, 2022 (GLOBE NEWSWIRE) -...

CAMBRIDGE, Mass., May 31, 2022 (GLOBE NEWSWIRE) -- EQRx, Inc. (Nasdaq: EQRX), a new type of pharmaceutical company committed to developing and delivering innovative medicines to patients at radically lower prices, today announced that management will participate in the following investo...

In a Phase 3 clinical trial, the addition of sugemalimab to chemotherapy improved median overall survival by 8.5 months versus placebo plus chemotherapy in people with previously untreated Stage IV non-small cell lung cancer (NSCLC) In a Phase 2 trial, sugemalimab treatment resulted...

EQRx, Inc. (EQRX) Q1 2022 Results Conference Call May 13, 2022 08:00 AM ET Company Participants Neil Swami - Head-Investor Relations Melanie Nallicheri - President and Chief Executive Officer Eric Hedrick - Chief Physician Executive Jami Rubin - Chief Financial Officer Conference Call Partici...

EQRx press release (NASDAQ:EQRX): Q1 GAAP EPS of $0.04 beats by $0.28. Cash and cash equivalents totaled $1.6 billion at March 31, 2022. Based on EQRx’s current operating plan, management believes EQRx has sufficient capital resources to fund anticipated operations into 2025. For fur...

New data on lead oncology programs aumolertinib and sugemalimab to be presented at the 2022 ASCO Annual Meeting, including pre-specified interim overall survival (OS) data from the Phase 3 GEMSTONE-302 study of sugemalimab plus chemotherapy in first-line Stage IV NSCLC Continue to exp...

CAMBRIDGE, Mass., April 29, 2022 (GLOBE NEWSWIRE) -- EQRx, Inc. (Nasdaq: EQRX), a new type of pharmaceutical company committed to developing and delivering innovative medicines to patients at radically lower prices, today announced it will host a conference call and webcast on Friday, M...